Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of “Hold” from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has received an average recommendation of “Hold” from the seventeen brokerages that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $25.13.

A number of equities research analysts have commented on the stock. Morgan Stanley started coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price for the company. BTIG Research initiated coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Piper Sandler increased their target price on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their price target for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Finally, Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th.

Insider Activity at Hims & Hers Health

In other news, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now owns 169,803 shares in the company, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $38.92, for a total transaction of $450,732.52. Following the completion of the transaction, the chief financial officer now directly owns 112,933 shares in the company, valued at $4,395,352.36. This trade represents a 9.30 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,167,913 shares of company stock worth $34,303,787. 17.71% of the stock is owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Hedge funds have recently bought and sold shares of the stock. Yong Rong HK Asset Management Ltd bought a new stake in shares of Hims & Hers Health in the fourth quarter worth about $41,104,000. Principal Financial Group Inc. increased its stake in Hims & Hers Health by 370.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock worth $33,024,000 after acquiring an additional 1,075,355 shares during the last quarter. Wellington Management Group LLP increased its stake in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after acquiring an additional 883,230 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $18,048,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Hims & Hers Health by 128.7% during the 4th quarter. Bank of New York Mellon Corp now owns 1,244,953 shares of the company’s stock valued at $30,103,000 after acquiring an additional 700,500 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 5.1 %

Shares of HIMS stock opened at $44.70 on Tuesday. The company has a 50 day moving average price of $30.50 and a 200-day moving average price of $23.43. Hims & Hers Health has a 52 week low of $9.14 and a 52 week high of $46.01. The firm has a market capitalization of $9.77 billion, a PE ratio of 101.60 and a beta of 1.35.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.